Metformin and uti
Pro Research Analysisby 
Searched over 200M research papers
Metformin and Urinary Tract Infections (UTIs): A Comprehensive Overview
Introduction to Metformin and UTIs
Metformin is a widely used first-line medication for managing type 2 diabetes (T2D). However, its impact on urinary tract infections (UTIs) in diabetic patients has been a subject of research. This article synthesizes findings from multiple studies to provide a clear understanding of the relationship between metformin use and the risk of UTIs.
Metformin and UTI Risk in Diabetic Patients
Comparative Efficacy and Safety of Antidiabetic Drug Regimens
A network meta-analysis evaluated the efficacy and safety of various antidiabetic agents added to metformin monotherapy in patients with inadequately controlled T2D. The study found that no therapy, including metformin, increased the risk of UTIs compared to placebo. However, sodium-glucose cotransporter-2 (SGLT2) inhibitors were associated with an increased risk of genital tract infections (GTIs) but not UTIs1.
Morbidity and Mortality Associated with UTIs
A large-scale study from Taiwan's National Health Insurance Research Database compared the morbidity and mortality associated with UTIs and sepsis between metformin users and nonusers. The study concluded that metformin use did not significantly alter the risks of UTI, recurrent UTI, or sepsis. However, it was associated with a significantly lower risk of death due to UTI or sepsis compared to nonuse of metformin2.
SGLT2 Inhibitors vs. Metformin
A systematic review and meta-analysis compared the cardiovascular benefits and infection risks of SGLT2 inhibitors and metformin. The findings indicated that while SGLT2 inhibitors increased the risk of genitourinary tract infections, the occurrence of UTIs was not statistically significant when compared to metformin. This suggests that metformin does not elevate the risk of UTIs relative to SGLT2 inhibitors3.
Metformin and Urinary Stone Formation
Impact on Struvite Stone Formation
Research has also explored the role of metformin in the formation of urinary stones, particularly struvite stones, in diabetic patients with UTIs. The study demonstrated that high concentrations of glucose, metformin, and protein could enhance the formation of struvite stones in an artificial urine medium infected with methicillin-resistant Staphylococcus aureus (MRSA). This suggests that while metformin itself may not increase UTI risk, it could contribute to urinary stone formation under certain conditions4.
Conclusion
In summary, current research indicates that metformin does not significantly increase the risk of UTIs in patients with type 2 diabetes. However, it is associated with a lower risk of death due to UTI or sepsis. While metformin may contribute to urinary stone formation in the presence of other factors like hyperglycemia and proteinuria, it remains a safe and effective first-line treatment for T2D with respect to UTI risk. Clinicians should consider these findings when prescribing metformin, especially in patients with a history of urinary stones or recurrent UTIs.
Sources and full results
Most relevant research papers on this topic
Comparative Efficacy and Safety of Antidiabetic Drug Regimens Added to Metformin Monotherapy in Patients with Type 2 Diabetes: A Network Meta-Analysis
Adding different antidiabetic agents to metformin can have varying effects on HbA1c, BW, SBP, hypoglycemia, UTI, and GTI, impacting clinician choice when selecting adjunctive therapy.
Meta-Analysis
Rigorous Journal
Highly CitedRole of Metformin in Morbidity and Mortality Associated with Urinary Tract Infections in Patients with Type 2 Diabetes
Metformin use in patients with type 2 diabetes is associated with a lower risk of death due to urinary tract infections or sepsis compared to nonuse.
Observational StudyRigorous JournalThe Cardiovascular Benefits and Infections Risk of SGLT2i versus Metformin in Type 2 Diabetes: A Systemic Review and Meta-Analysis
SGLT2i provides similar antihyperglycemic effects, additional cardiovascular benefits, and a potential reproductive tract infection risk compared to metformin, making it a good choice for patients with metformin intolerance or resistance.
Meta-AnalysisRigorous JournalEffects of Glucose, Metformin, and Protein on Formation of Flower-like Nanocomposites of Struvite in Infected Artificial Urine Medium by Methicillin-resistant Staphylococcus aureus (MRSA): New Report
Therapy of MDR bacteria, hyperglycemia, and proteinuria can decrease urinary stone formation in diabetic patients with UTIs.
Diabetes mellitus without metformin intake is associated with worse oncologic outcomes after radical nephroureterectomy for upper tract urothelial carcinoma.
Diabetic upper tract urothelial carcinoma patients without metformin use have significantly worse oncologic outcomes than those who use metformin and non-diabetics.
Observational StudyRisk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.
Metformin use in type 2 diabetes patients does not increase the risk of lactic acidosis or blood lactate levels compared to other anti-hyperglycemic treatments.
Meta-Analysis
Very Rigorous JournalHighly CitedMetformin, an AMPK activator, stimulates the phosphorylation of aquaporin 2 and urea transporter A1 in inner medullary collecting ducts.
Metformin may be a novel therapeutic option for congenital nephrogenic diabetes insipidus due to V2R mutations, as it increases urine-concentrating ability by mimicking vasopressin's mechanisms.
In Vitro StudyIs metformin poised for a second career as an antimicrobial?
Metformin shows potential as an antimicrobial agent, improving outcomes in patients with tuberculosis and a wide range of other infections.
Systematic ReviewHighly CitedMetformin in cancer.
Metformin may have potential anti-tumorgenic effects, but its effectiveness in treating cancer remains inconclusive.
Highly CitedMetformin and Its Benefits for Various Diseases
Metformin offers benefits for various diseases and aging, with potential underlying mechanisms still unclear.
Highly Cited